SLC6A3 anticorps (C-Term)

N° du produit ABIN361429

Détail du produit anti-SLC6A3 anticorps

Antigène: SLC6A3 (Solute Carrier Family 6 (Neurotransmitter Transporter, Dopamine), Member 3 (SLC6A3))

Épitope: C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SLC6A3 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Specificité: Specific for the ~88k DAT protein in Western blots. Cross-reaction with rat observed.

Réactivité croisée: Humain, Souris, Non-Human Primate

Purification: Antigen Affinity Purified from Pooled Serum

Immunogène: Synthetic peptide corresponding to amino acid residues from the intracellular C-terminal region conjugated to KLH

Information d'application

Indications d'application: Recommended Dilution: WB: 1:1000 IHC: (frozen sections, formaldehyde fixed tissue, unpublished observations): 1:1000 Quality Control: Western blots performed on each lot.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: 100 μL in 10 mM HEPES (  pH 7.5), 150 mM NaCl, 100 μg per ml BSA and 50 % glycerol.

Stock: -20 °C

Détails sur SLC6A3

Antigène: SLC6A3 (Solute Carrier Family 6 (Neurotransmitter Transporter, Dopamine), Member 3 (SLC6A3))

Autre désignation: SLC6A3 (SLC6A3 Produits)

Synonymes: anticorps DAT, anticorps SLC6A3, anticorps Dat1, anticorps DAT1, anticorps PKDYS, anticorps solute carrier family 6 member 3, anticorps solute carrier family 6 (neurotransmitter transporter), member 3, anticorps Sodium-dependent dopamine transporter, anticorps solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, anticorps SLC6A3, anticorps slc6a3, anticorps dat-1, anticorps Slc6a3

Sujet: The dopamine transporter (DAT) is responsible for the reaccumulation of dopamine after it has been released. DAT antibodies and antibodies for other markers of catecholamine biosynthesis are widely used as markers for dopaminergic and noradrenergic neurons in a variety of applications including depression, schizophrenia, Parkinson?s disease and drug abuse (Kish et al., 2001, Zhu et al., 2000, Zhu et al., 1999). Levels of DAT protein expression are altered by chronic drug administration (Wilson et al., 1996). Anti-Dopamine Transporter Western blot of human caudate lysate showing specific immunolabeling of the ~88k DAT protein.

Poids moléculaire: '88 kDa

ID gène: 6531

UniProt: Q01959

Pathways: Dopaminergic Neurogenesis